open access

Vol 14, No 2 (2009)
Untitled
Published online: 2009-03-01
Submitted: 2008-10-22
Get Citation

Concurrent hyperfractionated radiotherapy and chemotherapy for patients with limited small-cell lung cancer. Results from a single institution

Josep M. SOLÉ MONNÉ, Miquel Macià GARAU, Maria José CAMBRA SERÉS, Remei BLANCO GUERRERO, Jesús MONTESIONS MUÑOZ, Enrique GALLARDO DIAZ, Romà BESTÚS PIULACHS, Ricard MESIA NIN, Carlota MONFA BINEFAR
DOI: 10.1016/S1507-1367(10)60021-1
·
Rep Pract Oncol Radiother 2009;14(2):46-52.

open access

Vol 14, No 2 (2009)
Untitled
Published online: 2009-03-01
Submitted: 2008-10-22

Abstract

Background

Concurrent use of chemotherapy and twice-a-day hyperfractionated radiotherapy is an efficacious scheme to control limited disease (LD) small-cell lung cancer (SCLC).

Aim

Our main objective was to estimate initial results in overall survival for patients with LD-SCLC treated with concomitant chemotherapy and hyperfractionated thoracic radiotherapy in routine practice. Response to treatment and toxicity were also assessed.

Material and Methods

Forty-nine patients with confirmed LD-SCLC were treated at the Department of Radiotherapy of the Hospital General de Catalonia (Spain) from December 1999 to February 2007. The chemotherapy regimen was cisplatin (80 mg/m2) on day 1 and etoposide (100 mg/m2) on days 1, 2, and 3, every 21 day. The target dose to the tumor volume was 45 Gy. Prophylactic cranial irradiation (PCI), consisting of 30 Gy delivered in 15 fractions, was prescribed for all patients with a response rate >75% (23 of 30 patients).

Results

Median follow-up was 12 months (range, 6–58 months) and median overall survival was 28.9 months. Two-year and 4-year survival rates were 56.4% and 30.1%, respectively. At 2 years, specific survival, local control, and systemic control were 64.2%, 88.8%, and 46.8%, respectively. Myelotoxicity and oesophagitis were the most severe toxicities.

Conclusions

The combined schedule – hyperfractionated irradiation plus concurrent chemotherapy – can be applied in routine practice in the context of early radiotherapy, which is considered standard treatment, with acceptable toxicity and similar results to those described in the literature.

Abstract

Background

Concurrent use of chemotherapy and twice-a-day hyperfractionated radiotherapy is an efficacious scheme to control limited disease (LD) small-cell lung cancer (SCLC).

Aim

Our main objective was to estimate initial results in overall survival for patients with LD-SCLC treated with concomitant chemotherapy and hyperfractionated thoracic radiotherapy in routine practice. Response to treatment and toxicity were also assessed.

Material and Methods

Forty-nine patients with confirmed LD-SCLC were treated at the Department of Radiotherapy of the Hospital General de Catalonia (Spain) from December 1999 to February 2007. The chemotherapy regimen was cisplatin (80 mg/m2) on day 1 and etoposide (100 mg/m2) on days 1, 2, and 3, every 21 day. The target dose to the tumor volume was 45 Gy. Prophylactic cranial irradiation (PCI), consisting of 30 Gy delivered in 15 fractions, was prescribed for all patients with a response rate >75% (23 of 30 patients).

Results

Median follow-up was 12 months (range, 6–58 months) and median overall survival was 28.9 months. Two-year and 4-year survival rates were 56.4% and 30.1%, respectively. At 2 years, specific survival, local control, and systemic control were 64.2%, 88.8%, and 46.8%, respectively. Myelotoxicity and oesophagitis were the most severe toxicities.

Conclusions

The combined schedule – hyperfractionated irradiation plus concurrent chemotherapy – can be applied in routine practice in the context of early radiotherapy, which is considered standard treatment, with acceptable toxicity and similar results to those described in the literature.

Get Citation

Keywords

small-cell lung cancer; radiotherapy

About this article
Title

Concurrent hyperfractionated radiotherapy and chemotherapy for patients with limited small-cell lung cancer. Results from a single institution

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 14, No 2 (2009)

Pages

46-52

Published online

2009-03-01

DOI

10.1016/S1507-1367(10)60021-1

Bibliographic record

Rep Pract Oncol Radiother 2009;14(2):46-52.

Keywords

small-cell lung cancer
radiotherapy

Authors

Josep M. SOLÉ MONNÉ
Miquel Macià GARAU
Maria José CAMBRA SERÉS
Remei BLANCO GUERRERO
Jesús MONTESIONS MUÑOZ
Enrique GALLARDO DIAZ
Romà BESTÚS PIULACHS
Ricard MESIA NIN
Carlota MONFA BINEFAR

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl